

## Cabozantinib, Met and VEGFR2 inhibitor

Catalog	Unit
TBI3231-5MG	5 mg
TBI3231-25MG	25 mg

### Product Details

**Formal Name:** N-(4-((6,7-Dimethoxyquinolin-4-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

**Alternate Names:** XL-184; BMS-907351

**Molecular Formula:** C<sub>28</sub>H<sub>24</sub>FN<sub>3</sub>O<sub>5</sub>

**Formula Weight:** 501.51

**CAS Number:** 849217-68-1


**Purity:** >98%

**Formulation:** powder

**Solubility:** Soluble in DMSO.

**Storage:** -20°C

**Stability:** ≥ 1 year.



### Applications

Met and VEGFR2 inhibitor

### Functions

Novel inhibitor of c-met and VEGFR2 kinase activity, IC<sub>50</sub>=3.5 nM and 35 pM respectively. Inhibits MET-activating kinase domain mutations Y1248H, D1246N or K1262R, IC<sub>50</sub>=3.8, 11.8 and 14.6 nM respectively. In cellular assays it inhibits the following kinases: MET, VEGF2, KIT, FLT3 and AXL, IC<sub>50</sub>=7.8, 1.9, 5.0, 7.5 and 42 μM respectively. Eliminated approximately 80% of vasculature in spontaneous pancreatic islet tumors over 7 days in a mouse model. Clinically useful anticancer agent.

### Application Procedures

First dissolved in DMSO, then diluted to aqueous buffer. Solutions in DMSO may be stored at -20°C for up to 1 month.

**For research use only.**